Results 101 to 110 of about 70,416 (256)
Selective use of sorafenib in the treatment of thyroid cancer
, 2016 Fabián Pitoia, Fernando Jerkovich Division of Endocrinology, Hospital de Clinicas – University of Buenos Aires, Buenos Aires, Argentina Abstract: Sorafenib is a multiple kinase inhibitor (MKI) approved for the treatment of primary advanced
Pitoia F, Jerkovich F
core
Journal of Ultrasound in Medicine, EarlyView.Patient‐derived xenograft (PDX) tumor models initiated in avian chorioallantoic membranes (CAM) are under investigation to evaluate the effectiveness of therapeutic options with the objective of personalizing treatments. CAM PDXs paired with ultra‐high frequency ultrasound (UHFUS) imaging could potentially constitute prospective high throughput assays ...
Sara Mar +5 more
wiley +1 more source
Genetic Mutations in Recurrent/Metastatic Papillary Thyroid Carcinoma
The Laryngoscope, EarlyView.We investigated the mutational landscape and prognostic implications of recurrent/metastatic papillary thyroid carcinoma using nationwide C‐CAT data from 348 patients. CDKN2A, KMT2D, and concurrent TERT/BRAF mutations were independently associated with poorer overall survival, highlighting the potential prognostic value of comprehensive genomic ...
Hiromi Nagano +3 more
wiley +1 more source
Organoid Coculture Models for Cancer Research and Immunotherapy
Med Research, EarlyView.This review summarizes organoid coculture platforms, including submerged Matrigel culture, air–liquid interface, microfluidic/organoid‐on‐a‐chip, and 3D bioprinting, for reconstructing the tumor microenvironment to study tumor–stroma/immune crosstalk, evaluate immunotherapies, and enable drug screening.
Zhuo Yang +9 more
wiley +1 more source
Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells
, 2013 Do Hyung Kim,1,2,* Young-Il Jeong,1,* Chung-Wook Chung,1 Cy Hyun Kim,1,2 Tae Won Kwak,1 Hye Myeong Lee,1 Dae Hwan Kang1,21National Research and Development Center for Hepatobiliary Cancer, Pusan National University Yangsan Hospital, 2School of Medicine ...
Kim DH +6 more
core
Hepatocellular carcinoma: sorafenib: for once age is not an issue.
, 2014 Are some patients with hepatocellular carcinoma just too old to be treated? More specifically, should the age of a patient influence the way sorafenib is prescribed? A new study has tried to address these questions, providing helpful information to guide
Jean-François Dufour +1 more
core +1 more source
The FGF/FGFR System in the Biology and Therapeutic Landscape of Pediatric CNS Tumors
Medicinal Research Reviews, EarlyView.ABSTRACT Central nervous system (CNS) tumors are the most common solid malignancies in children, comprising a highly heterogeneous group of neoplasms defined by distinct molecular alterations and clinical behaviors. Advances in molecular genetics have underscored the relevance of specific signaling pathways in driving pediatric tumorigenesis, among ...
Serena Filiberti +6 more
wiley +1 more source
, 2018 Lixia Fan,1,* Zhenglei He,1,* Sarah A Head,2 Yinghui Zhou,1 Ting Lu,1 Xulong Feng,1 Xueqing Zhang,1 Meng Zhang,1 Yongjun Dang,3 Xinghong Jiang,4 Minghua Wang1 1Department of Biochemistry and Molecular Biology, Medical College, Soochow University, Suzhou,
Wang M +10 more
core
Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma
, 2012 The combination of erlotinib with sorafenib is currently being investigated in a phase III RCT.
Pinter, Matthias +9 more
core +1 more source